Lympha Motus
A post-cancer care company
Lympha Motus is a spin-out from the Moore Research Group at Imperial College London. We study the biomechanics of the lymphatic and cardiovascular systems. The results of our research are used to design medical device technologies to improve patients’ lives as well as decrease the societal and economic costs of disease.
FaciliFlow
Lympha Motus founder Professor James E Moore Jr. invented FaciliFlow, a novel silicone-based medical device aiming to prevent breast cancer-related lymphoedema. The team developed FaciliFlow and are eager to apply for regulatory approval to fight against this life-changing and incurable condition.
Our Funders
NIHR i4i grant winners, 2020
Awarded joint first prize at the Siemens Healthineers external Innovation Think Tank Exhibition (eITT) 2022
Our Roadmap
Proof-of-concept preclinical trials successful
2017
£1.3m funding from NIHR i4i programme
Team formation
2020
U.S. patent issued
Identified first patient cohort to receive implants during clinical trials
2021
Lympha Motus Ltd. formation
Awarded joint first prize at the Siemens Healthineers external Innovation Think Tank Exhibition (eITT) 2022
Podium presentation at Gordon Research Conference on Lymphatics
Scientific meeting with MHRA to plan route to market entry
2022
Device R&D complete
2023
Design for clinical trials
Preclinical studies for safety and efficacy
First in human clinical trials
Regulatory approvals
2024
-
2030
Meet the Team
-
Prof. James E. Moore Jr.
INVENTOR AND FOUNDER
Lymphatics biomechanics researcher. Professor of medical device entrepreneurship at Imperial College London.
-
Kate Rowley, PhD., MBA
CEO
Leads health tech companies from start up to acquisition. Board member of 7 companies in the life sciences sector.
-
Alain Vella
R&D ENGINEER, CO-FOUNDER
Special interest in cancer biomechanics. Lead manufacturing and design engineer.
-
Arushri Swarup, PhD.
R&D ENGINEER & CO-FOUNDER
Focussed on medical device R&D for solutions to under-represented medical needs. Lead R&D and verification and validation testing engineer.
-
Patient and Public Involvement Group
Lymphoedema patients who provide insight and have a desire to prevent future patients developing breast cancer-related lymphoedema.
Advisory Board
-
Mr. Paul Thiruchelvam, Breast Surgeon
Clinical advisor on user requirements and clinical adoption. BCRL patient advocate.
-
Dr. Guido Giacalone, MD, PhD
Clinical advisor on user requirements and clinical adoption. Performed proof of concept trials.
-
James Barry, PhD.
R&D advisor on medical device development.
-
Dr. John Gonzalez-Carvajal
Medtech advisor on medical device design for the breast cancer surgery market.
-
Mr. Neil Roberts
Advisor for route to market strategy for patient impact.
-
Steven Proulx, PhD.
Regenerative medicine scientific advisor for lymphatics research.